Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with fusion and induction failure.
作者信息
Ding Yang Y, Stern Julie W, Jubelirer Tracey F, Wertheim Gerald B, Lin Fumin, Chang Fengqi, Gu Zhaohui, Mullighan Charles G, Li Yong, Harvey Richard C, Chen I-Ming, Willman Cheryl L, Hunger Stephen P, Li Marilyn M, Tasian Sarah K
机构信息
Children's Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research, PA, USA.
University of Pennsylvania Perelman School of Medicine, Department of Pediatrics, PA, USA.
出版信息
Haematologica. 2018 Sep;103(9):e427-e431. doi: 10.3324/haematol.2018.192088. Epub 2018 May 17.
Abstract
摘要
相似文献
1
Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with fusion and induction failure.鲁索替尼与化疗对一名费城染色体样急性淋巴细胞白血病伴融合及诱导失败患儿的临床疗效
Haematologica. 2018 Sep;103(9):e427-e431. doi: 10.3324/haematol.2018.192088. Epub 2018 May 17.
2
Sustained remission after ruxolitinib and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with novel NPHP3-JAK2 fusion.鲁索替尼和嵌合抗原受体T细胞疗法后持续缓解，桥接至第二次异基因造血干细胞移植，用于治疗复发的具有新型NPHP3-JAK2融合的费城染色体样B细胞前体急性淋巴细胞白血病。
Genes Chromosomes Cancer. 2022 Jan;61(1):55-58. doi: 10.1002/gcc.22995. Epub 2021 Sep 1.
3
Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.波纳替尼治疗费城染色体阳性急性淋巴细胞白血病患者的疗效和安全性：来自单一机构的病例系列
Int J Hematol. 2021 Aug;114(2):199-204. doi: 10.1007/s12185-021-03156-0. Epub 2021 Apr 27.
4
Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib.鉴定 RNPC3 为一种新型 JAK2 融合伙伴基因，其存在与包括鲁索利替尼在内的联合疗法治疗抵抗的 B 急性淋巴细胞白血病相关。
Mol Genet Genomic Med. 2020 Mar;8(3):e1110. doi: 10.1002/mgg3.1110. Epub 2019 Dec 30.
5
Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.芦可替尼/尼罗替尼联合治疗抑制费城染色体阳性 ALL 中的白血病起始细胞。
J Transl Med. 2017 Aug 30;15(1):184. doi: 10.1186/s12967-017-1286-5.
6
Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.伴有 CCDC88C-PDGFRB 融合的复发 BCR-ABL1 样急性淋巴细胞白血病患者中酪氨酸激酶抑制剂治疗的获益。
Int J Hematol. 2021 Feb;113(2):285-289. doi: 10.1007/s12185-020-03006-5. Epub 2020 Sep 19.
7
New Treatment Strategies for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.费城染色体阳性急性淋巴细胞白血病的新治疗策略
Curr Hematol Malig Rep. 2017 Apr;12(2):136-142. doi: 10.1007/s11899-017-0372-3.
8
Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.芦可替尼对一名JAK2阴性慢性粒单核细胞白血病-2型患者的疾病修饰活性。
Leuk Lymphoma. 2017 May;58(5):1271-1272. doi: 10.1080/10428194.2016.1225209. Epub 2016 Sep 23.
9
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.成人Ph+急性淋巴细胞白血病采用伊马替尼、化疗和移植的序贯治疗方法：GIMEMA LAL 0904研究的最终结果
Haematologica. 2016 Dec;101(12):1544-1552. doi: 10.3324/haematol.2016.144535. Epub 2016 Aug 11.
10
JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).《日本血液学会2018年血液系统恶性肿瘤实用指南：I. 白血病 - 3. 急性淋巴细胞白血病/淋巴细胞淋巴瘤（ALL/LBL）》
Int J Hematol. 2020 Oct;112(4):439-458. doi: 10.1007/s12185-020-02965-z. Epub 2020 Aug 18.
引用本文的文献
1
JAK2 in pediatric leukemia: mechanisms of pathogenesis and drug development - a narrative review.JAK2在儿童白血病中的发病机制及药物研发——一篇叙述性综述
Ann Med Surg (Lond). 2025 Mar 18;87(6):3410-3423. doi: 10.1097/MS9.0000000000003180. eCollection 2025 Jun.
2
Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities.儿童急性淋巴细胞白血病中的蛋白质组学：挑战与机遇
Diagnostics (Basel). 2023 Aug 24;13(17):2748. doi: 10.3390/diagnostics13172748.
3
BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases.BCR::ABL1样急性淋巴细胞白血病：一家机构对潜在可治疗靶点病例识别的经验
Mol Cytogenet. 2023 Jul 3;16(1):14. doi: 10.1186/s13039-023-00645-1.
4
Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article.费城样急性淋巴细胞白血病：从分子背景到骨髓移植作用的探索——综述文章。
Ann Hematol. 2023 Jun;102(6):1287-1300. doi: 10.1007/s00277-023-05241-2. Epub 2023 May 2.
5
Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia.针对B细胞急性淋巴细胞白血病中mTOR的新型药理学和饮食方法。
Front Oncol. 2023 Apr 14;13:1162694. doi: 10.3389/fonc.2023.1162694. eCollection 2023.
6
JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.JAK1 假激酶 V666G 突变体显性抑制 JAK3 磷酸化和 IL-2 信号通路。
Int J Mol Sci. 2023 Apr 6;24(7):6805. doi: 10.3390/ijms24076805.
7
Case Report: Whole genome sequencing identifies as a novel fusion partner in pediatric T-cell acute lymphoblastic leukemia.病例报告：全基因组测序鉴定出在小儿T细胞急性淋巴细胞白血病中作为一种新型融合伴侣。
Front Pediatr. 2023 Jan 10;10:1082986. doi: 10.3389/fped.2022.1082986. eCollection 2022.
8
Clinical screening for Ph-like ALL and the developing role of TKIs.Ph 样 ALL 的临床筛查和 TKI 的发展作用。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):594-602. doi: 10.1182/hematology.2022000357.
9
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.儿童启发方案一线治疗成人急性淋巴细胞白血病患者中枢神经系统复发的发生率、治疗和转归：回顾性多中心 Campus ALL 研究。
Br J Haematol. 2023 Feb;200(4):440-450. doi: 10.1111/bjh.18537. Epub 2022 Nov 6.
10
Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies.急性淋巴细胞白血病的改变：卓越精准医学策略的分子见解
Front Cell Dev Biol. 2022 Jul 12;10:942053. doi: 10.3389/fcell.2022.942053. eCollection 2022.
本文引用的文献
1
IKZF1 Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.IKZF1 在小儿 B 细胞前体急性淋巴细胞白血病中定义了一种新的与微小残留病灶相关的非常差预后的最小残留病灶依赖性预后模型。
J Clin Oncol. 2018 Apr 20;36(12):1240-1249. doi: 10.1200/JCO.2017.74.3617. Epub 2018 Mar 2.
2
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.高危B淋巴细胞白血病中可靶向的激酶基因融合：来自儿童肿瘤协作组的一项研究
Blood. 2017 Jun 22;129(25):3352-3361. doi: 10.1182/blood-2016-12-758979. Epub 2017 Apr 13.
3
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.成人费城染色体样急性淋巴细胞白血病的高频率及不良预后
J Clin Oncol. 2017 Feb;35(4):394-401. doi: 10.1200/JCO.2016.69.0073. Epub 2016 Nov 21.
4
Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.芦可替尼纳入针对B前体急性淋巴细胞白血病中一种新型JAK2 F694L突变的剂量强化疗法。
Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26328. Epub 2016 Nov 15.
5
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.PI3K/mTOR与JAK或ABL联合抑制在Ph样急性淋巴细胞白血病小鼠异种移植模型中的强效疗效。
Blood. 2017 Jan 12;129(2):177-187. doi: 10.1182/blood-2016-05-707653. Epub 2016 Oct 24.
6
EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.儿童 B 细胞前体急性淋巴细胞白血病（BCP-ALL）中 EBF1-PDGFRB 融合：遗传学特征和临床意义。
Blood. 2016 May 5;127(18):2214-8. doi: 10.1182/blood-2015-09-670166. Epub 2016 Feb 12.
7
Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia.急性淋巴细胞白血病中截短型促红细胞生成素受体重排
Cancer Cell. 2016 Feb 8;29(2):186-200. doi: 10.1016/j.ccell.2015.12.013.
8
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).鲁索替尼用于复发或难治性实体瘤、白血病或骨髓增殖性肿瘤儿童的1期剂量研究：儿童肿瘤学组1期联合研究（ADVL1011）。
Pediatr Blood Cancer. 2015 Oct;62(10):1717-24. doi: 10.1002/pbc.25575. Epub 2015 May 13.
9
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.异基因移植前及移植后早期的免疫球蛋白重链可变区（IgH）-V（D）J下一代测序微小残留病（NGS-MRD）检测可明确极低风险和极高风险的急性淋巴细胞白血病（ALL）患者。
Blood. 2015 May 28;125(22):3501-8. doi: 10.1182/blood-2014-12-615757. Epub 2015 Apr 10.
10
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.Ph 样急性淋巴细胞白血病中可靶向的激酶激活病变。
N Engl J Med. 2014 Sep 11;371(11):1005-15. doi: 10.1056/NEJMoa1403088.
Zotero 插件